Exelixis outlines growth strategy as CABOMETYX franchise hits $2.12B, eyes 2026 zanzalintinib launch
Source: SeekingAlpha
2026-02-10 20:55:10 ET
More on Exelixis
- Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript
- Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval
- Exelixis: High-Growth Oncology Name Trading At A Discount
- Exelixis Non-GAAP EPS of $0.97 beats by $0.16, revenue of $598.66M misses by $2.44M
- Exelixis Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Exelixis outlines growth strategy as CABOMETYX franchise hits $2.12B, eyes 2026 zanzalintinib launch
Exelixis Inc.
NASDAQ: EXEL
EXEL Trading
0.07% G/L:
$40.86 Last:
740,799 Volume:
$41.665 Open:
EXEL Latest News
February 28, 2026 04:57:00 am
3 Reasons Exelixis Stock Could Deliver Market?Beating Returns Over the Next Decade
February 24, 2026 04:05:00 pm
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
February 24, 2026 10:58:00 am
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
February 20, 2026 04:05:00 pm
Exelixis: The Cash?Generating Biotech That I Think Deserves a Closer Look in 2026
EXEL Stock Data
$11,614,618,641
260,551,394
1.54%
313
N/A
Biotechnology & Life Sciences
Healthcare
US
Alameda
